Anticoagulation in COVID-19: why, what, and when
Coronavirus disease-2019, which was declared by the WHO as a global pandemic in March 2020, was seen to be associated with high incidence of thromboembolic complication. The use of prophylactic anticoagulation was seen to have a survival benefit, especially in high-risk patients. The use of higher t...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Egyptian Journal of Chest Disease and Tuberculosis |
Subjects: | |
Online Access: | http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2021;volume=70;issue=5;spage=12;epage=15;aulast=Taema |